Key takeaway from this announcement: Its the same thing as the...

Key takeaway from this announcement: Its the same thing as the Hologic deal.

Producing a working prototype of a lateral flow test for use with custom LDX readers with a mobile phone application.

Ongoing revenues likely to be received from this the same way they will be from Hologic:

- Manufacturing of the tests.
- Manufacturing of the custom readers

Refer to the original BDI announcement last year:




You could look at the overall Hologic structure for FFN on how these deals work.

4 phase play:

- Initial feasibility = Initial revenue payments = $200,000USD received in 2023
- Confirm the test can read the biomarkers Build prototypes and custom platforms = Second and Third payments = $700,000USD - $1MillionUSD 2024/25
- Completed product = Ongoing annuities from manufacturing of tests = $X